PARP1 and cancer: Based on accumulating research results on synthetic lethality observed between PARP inhibition and BRCA mutation status,119, 120 a clinical evaluation of olaparib was initiated in 2005, where 63% of patients cancer with germline BRCA1 or BRCA2 mutations (gBRCAm) exhibited durable clinical benefit.121